What do systematic reviews say?

BM‐MSC vs no treatment

BM‐MSC showed no clear difference in overall survival compared with no treatment (low certainty).

• Cell‐based therapies for amyotrophic lateral sclerosis/motor neuron disease 2019 · Cochrane Headline outcomes only
  RR 1.07 [0.94, 1.22]
  1 study · 64 participants
  Low

Pre-radiotherapy extraction of healthy molar teeth vs Conservative treatment (leaving the teeth in place during radiotherapy, with oral health education and disease prevention: oral hygiene, fluoride, diet advice)

The review found no eligible studies for this question.

• Dental extractions prior to radiotherapy to the jaws for reducing post‐radiotherapy dental complications 2013 · Cochrane All outcomes
  no estimate extracted
  0 studies
  No studies found

Pre-radiotherapy extraction of diseased molar teeth vs Conservative treatment (restoration of the teeth and leaving them in place during radiotherapy, with oral health education and disease prevention: oral hygiene, fluoride, diet advice)

The review found no eligible studies for this question.

• Dental extractions prior to radiotherapy to the jaws for reducing post‐radiotherapy dental complications 2013 · Cochrane All outcomes
  no estimate extracted
  0 studies
  No studies found

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported
• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA1 only compared with no RRSO according to BRCA mutation status (very low certainty).

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 0.3 [0.17, 0.52]
  3 studies · 2548 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO according to BRCA mutation status

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA2 only compared with no RRSO according to BRCA mutation status (very low certainty).

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 0.44 [0.23, 0.85]
  2 studies · 2122 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: BRCA1 or BRCA2 compared with no RRSO (very low certainty).

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 0.32 [0.19, 0.54]
  3 studies · 2548 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

It is very uncertain whether risk‐reducing salpingo‐oophorectomy (RRSO) changes overall survival: RRSO and RRM vs no RRSO compared with no RRSO (very low certainty).

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  HR 0.14 [0.02, 0.98]
  1 study · 261 participants
  Very low

Risk‐reducing salpingo‐oophorectomy (RRSO) vs no RRSO

• Risk‐reducing bilateral salpingo‐oophorectomy in women with BRCA1 or BRCA2 mutations 2018 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported